SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Eva Maria Ciruelos, Tomás Pascual, Isabel Blancas, Maria Borrell, Rafael Villanueva-Vázquez, Barbara Adamo, Manuel Alva Bianchi, Lidia Carnerero Córdoba, Mireia Melé Olivé, Juan Miguel Cejalvo, Javier Salvador Bofill, Angelica Ferrando-Diez, Yann Izarzugaza Peron, Aranzazu Fernández, Xavier Gonzalez, Guillermo Villacampa, Mariana Paes Dias, Juan Manuel Ferrero-Cafiero, Mafalda Oliveira
Institutions: Hospital Universitario 12 De Octubre, Hospital Clínic de Barcelona, Solti, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Instituto de Investigación Biosanitaria de Granada, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Català d'Oncologia, Hospital Universitari Sant Joan de Reus, Hospital Clínico Universitario de Valencia, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Hospital Universitario Fundación Jiménez Díaz, UNC Lineberger Comprehensive Cancer Center, Instituto Oncológico Dr. Rosell, Hospital General de Catalunya
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410805145